Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.55 |
| ▸ | CA12 | O43570 | 9/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 7/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10061910 | 0.90 | MAPT (0.55) | CA2CA12KDM4ECA9GAA | |
| SCHEMBL10061887 | 0.82 | ALDH1A1 (0.46) | CA2CA12KDM4ECA9ALDH1A1 | |
| SCHEMBL30241961 | 0.80 | CA2 (0.59) | CA2CA12KDM4ECA9GAA | |
| SCHEMBL14666848 | 0.80 | CA2 (0.59) | CA2CA12KDM4ECA9GAA | |
| SCHEMBL8821790 | 0.77 | CA2 (0.55) | CA2CA12KDM4ECA9GAA | |
| SCHEMBL4353983 | 0.77 | MAPT (0.61) | CA2CA12KDM4ECA9GAA | |
| SCHEMBL4346769 | 0.77 | CASP1 (0.62) | CA2CA12KDM4ECA9GAA | |
| SCHEMBL4345738 | 0.77 | ALDH1A1 (0.71) | CA2CA12KDM4ECA9GAA | |
| SCHEMBL4345732 | 0.77 | ALDH1A1 (0.71) | CA2CA12KDM4ECA9GAA | |
| SCHEMBL8821791 | 0.77 | CA2 (0.55) | CA2CA12KDM4ECA9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030039-B2 | Anti-cancer agent and cancer cell killing method | IHI CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-10030039-B2 | Anti-cancer agent and cancer cell killing method | IHI CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20170240581-A1 | ANTI-CANCER AGENT AND CANCER CELL KILLING METHOD | ISHIKAWA, YOSHIHIRO (JP) | 2017-08-24 | — | — | US | disclosed |
| US-20170240581-A1 | ANTI-CANCER AGENT AND CANCER CELL KILLING METHOD | ISHIKAWA, YOSHIHIRO (JP) | 2017-08-24 | — | — | US | disclosed |
| US-9505732-B2 | Auto magnetic metal salen complex compound | IHI CORPORATION (JP) | 2016-11-29 | — | — | US | disclosed |
| US-9505732-B2 | Auto magnetic metal salen complex compound | IHI CORPORATION (JP) | 2016-11-29 | — | — | US | disclosed |
| EP-2733713-A1 | MATERIAL FOR ELECTRIC DOUBLE-LAYER CAPACITOR | IHI Corporation (JP) | 2014-05-21 | — | — | EP | disclosed |
| US-20120029167-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | YOSHIHIRO ISHIKAWA (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120029167-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | YOSHIHIRO ISHIKAWA (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029167-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | SDHB, SDHA, SLC40A1 | CA2 927/4885CA12 878/4885KDM4E 2197/4885 |
| US-20170240581-A1 | ANTI-CANCER AGENT AND CANCER CELL KILLING METHOD | BOD1L1, NUMA1, BUB1 | CA2 385/4885CA12 1136/4885KDM4E 3993/4885 |
| US-10030039-B2 | Anti-cancer agent and cancer cell killing method | BOD1L1, NUMA1, BUB1 | CA2 385/4885CA12 1136/4885KDM4E 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.